Sotagliflozin is in clinical development for the treatment of type 2 diabetes mellitus (T2DM). T2DM is a common, lifelong condition that causes the level of glucose in the blood to become too high. It is caused by problems with a chemical in the body (hormone) called insulin, which is produced in the pancreas and is responsible for controlling the amount of glucose in the blood. There are two main types of diabetes: type 1 – where the pancreas does not produce any insulin, and type 2 – where the pancreas does not produce enough insulin or body cells do not react to insulin.
Sotagliflozin is one of a new class of drugs that increase elimination of glucose in the urine. They offer the advantages of a reduced risk of low blood sugar. Sotagliflozin reduces the reabsorption of glucose from the intestines and kidneys, thus improving blood glucose control in diabetes mellitus. If licensed, sotagliflozin will offer an additional treatment option for patients with T2DM.
The current standard of care for patients with hypercholesterolaemia is primarily statins which are capable of reducing LDL‐C. There is however a subset of patients who are unable
to reach LDL‐C goals despite maximally tolerated oral lipid lowering therapy. Inclisiran is a medicinal product that inhibits a protein called PCSK9 especially present on the liver cells
leading to a decrease in circulating LDL‐C. If licensed, inclisiran will offer an additional treatment option for patients with primary hypercholesterolaemia as adjunctive therapy to diet and in combination with other lipid‐lowering therapies.